Pharmacology Research and Perspectives 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Massive presence of off ‐label medicines in Danish neonatal departments: A nationwide survey using national hospital purchase data
In conclusion, off-label medication in the Danish neonatal departments is widespread. The pharmaceutical industry is unlikely to solve this problem, a nd we may for a very long time be occasionally forced to use off-label medication. Practical solution must therefore come from multidisciplinary clinical and academic collaboration. Use of formulation list as guidance for prescriptions and NICU-friendly galenic formulations may mitigate the problem temporarily while waiting for definitive studies. (Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - December 22, 2022 Category: Drugs & Pharmacology Authors: Christina Gade,
Stine Trolle,
Mette ‐Louise Mørk,
Anna Lewis,
Peter Fruergaard Andersen,
Thorkild Jacobsen,
Jon Andersen,
Ulrik Lausten‐Thomsen Tags: ORIGINAL ARTICLE Source Type: research
Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS ‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19
Left: CONSORT flow chart. Right: ABBV-47D11 Dose –Response for SARS-CoV-2 Viral Load AUC of Change from Baseline to Day 15. AUC: area under the curve; Box plots represent 25th/75th percentiles, median (solid line), mean (dashed line), whiskers represent min-max values, and dots represent individual patient data. AbstractABBV-47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS-CoV-2. This first-in-human safety, pharmacokinetics, and antiviral pharmacodynamic assessment in patients with COVID-19 provide an initial evaluation of this an...
Source: Pharmacology Research and Perspectives - December 21, 2022 Category: Drugs & Pharmacology Authors: Mohamad Shebley,
Stanley Wang,
Izna Ali,
Preethi Krishnan,
Rakesh Tripathi,
Joseph M. Reardon,
John Cafardi,
Galia Rahav,
Yoseph Caraco,
Jihad Slim,
Fadi Al Akhrass,
Mengjia Yu,
Yiran Hu,
Rosa De Abreu Ferreira,
Negar N. Alami Tags: ORIGINAL ARTICLE Source Type: research
An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup
Time profile of plasma ethosuximide concentrations according to formulation. AbstractEthosuximide, the first-line therapy for childhood absence epilepsy, is currently formulated as a syrup (Zarontin ®, Pfizer) with a bitter taste and high sugar content, poorly adapted to children, and a ketogenic diet. The collaborative European FP7 project KIEKIDS aimed at developing an innovative sugar-free, tasteless formulation convenient for pediatric use. This dual Phase-I study evaluated two granule for mulations based on lipid multiparticulate (LMP) technology. Two panels of 6 healthy adult volunteers underwent a randomized, place...
Source: Pharmacology Research and Perspectives - December 20, 2022 Category: Drugs & Pharmacology Authors: L éonore Diezi,
Kim Dao,
Vincent Jullien,
Caroline Roussel‐Maupetit,
Ingrid Burton,
Pascal André,
Carine Bardinet,
Laura E. Rothuizen,
Haithem Chtioui,
Maria A. Manso‐Silvan,
Catherine Guittet,
Françoise Brunner‐Ferber,
Francois Vande Tags: ORIGINAL ARTICLE Source Type: research
